The management impact of clinically significant incidental lesions detected on staging FDG PET-CT in patients with non-small cell lung cancer (NSCLC): An analysis of 649 cases

Lin, Michael; Ambati, Chaitanya

doi:10.1016/j.lungcan.2011.11.024

Cited by 13 publications

(2 citation statements)

References 17 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 30% of focal FDG uptake can be indicative of malignancy, whereas a diffuse pattern of FDG uptake usually indicates a benign cause. In the findings of one study, FDG PET/CT identified a second primary malignancy or premalignant lesion in 3% of patients with NSCLC, a finding that changed management from a curative intent to palliation in 27% of patients (56).…”

Section: Detection Of a Second Primary Malignancymentioning

confidence: 99%

Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non–Small Cell Lung Cancer

et al. 2018

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related mortality in the United States, and accurate staging plays a vital role in determining prognosis and treatment. The recently revised eighth edition of the TNM staging system for lung cancer defines new T and M descriptors and updates stage groupings on the basis of substantial differences in survival. There are new T descriptors that are based on the findings at histopathologic examination, and T descriptors are reassigned on the basis of tumor size and extent. No changes were made to the N descriptors in the eighth edition of the TNM staging of lung cancer, because the four N categories that are based on the location of the diseased nodes can be used to consistently predict prognosis. The eighth edition includes a new M1b descriptor for patients with a single extrathoracic metastatic lesion in a single organ (M1b), because they have better survival and different treatment options, compared with those with multiple extrathoracic lesions (M1c). Examination with fluorine 18 fluorodeoxyglucose (FDG) PET/CT is the standard of care and is an integral part of the clinical staging of patients with lung cancer. To provide the treating physicians with accurate staging information, radiologists and nuclear medicine physicians should be aware of the updated classification system and should be cognizant of the site-specific strengths and limitations of FDG PET/CT. In this article, the eighth edition of the TNM staging system is reviewed, as well as the role of FDG PET/CT in the staging of non-small cell lung carcinoma. ©

show abstract

Section: Detection Of a Second Primary Malignancymentioning

confidence: 99%

Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non–Small Cell Lung Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…This can result in a vast array of unexpected findings remote from the primary region of abnormality and interest. Incidental second primary malignancies, reported in up to 3.1% of PET/CT, are suspected when focal increased metabolic activity is detected in a location unusual for metastatic spread of the patient's known malignancy, and when not interpreted as a physiological site of uptake . Traditional medicine encourages the formulation of a single, unifying diagnosis, however, multiple comorbidities frequently exist in oncology patients, including both benign and malignant causes, with a higher prevalence of synchronous or metachronous malignancy compared with the healthy .…”

Section: Introductionmentioning

confidence: 99%

Prevalence of non ¹⁸F‐fluorodeoxyglucose‐avid incidental findings of clinical significance on whole body positron emission tomography/computed tomography: A review of 500 consecutive cases

et al. 2017

View full text Add to dashboard Cite

show abstract

Diagnostic Applications of Nuclear Medicine: Lung and Mediastinal Tumors

et al. 2022

View full text Add to dashboard Cite

The management impact of clinically significant incidental lesions detected on staging FDG PET-CT in patients with non-small cell lung cancer (NSCLC): An analysis of 649 cases

Cited by 13 publications

References 17 publications

Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non–Small Cell Lung Cancer

Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non–Small Cell Lung Cancer

Prevalence of non ¹⁸F‐fluorodeoxyglucose‐avid incidental findings of clinical significance on whole body positron emission tomography/computed tomography: A review of 500 consecutive cases

Diagnostic Applications of Nuclear Medicine: Lung and Mediastinal Tumors

Contact Info

Product

Resources

About

The management impact of clinically significant incidental lesions detected on staging FDG PET-CT in patients with non-small cell lung cancer (NSCLC): An analysis of 649 cases

Cited by 13 publications

References 17 publications

Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non–Small Cell Lung Cancer

Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non–Small Cell Lung Cancer

Prevalence of non 18F‐fluorodeoxyglucose‐avid incidental findings of clinical significance on whole body positron emission tomography/computed tomography: A review of 500 consecutive cases

Diagnostic Applications of Nuclear Medicine: Lung and Mediastinal Tumors

Contact Info

Product

Resources

About

Prevalence of non ¹⁸F‐fluorodeoxyglucose‐avid incidental findings of clinical significance on whole body positron emission tomography/computed tomography: A review of 500 consecutive cases